# Safety and Tolerability of Repeat Courses of IM Alefacept

> **NCT00233662** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 400 (—)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Alefacept

## Key facts

- **NCT ID:** NCT00233662
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12-01
- **Primary completion:** —
- **Final completion:** 2005-12-01
- **Target enrollment:** 400 (—)
- **Last updated:** 2023-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233662, "Safety and Tolerability of Repeat Courses of IM Alefacept". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00233662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*